- Home
- VRNS vs MRUS Comparison
VRNS vs MRUS Comparison
Compare VRNS & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNS
- MRUS
- Stock Information
- Founded
- VRNS 2004
- MRUS 2003
- Country
- VRNS United States
- MRUS Netherlands
- Employees
- VRNS N/A
- MRUS N/A
- Industry
- VRNS Computer Software: Prepackaged Software
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- VRNS Technology
- MRUS Health Care
- Exchange
- VRNS Nasdaq
- MRUS Nasdaq
- Market Cap
- VRNS 4.4B
- MRUS 5.1B
- IPO Year
- VRNS 2014
- MRUS 2016
- Fundamental
- Price
- VRNS $56.31
- MRUS $69.01
- Analyst Decision
- VRNS Buy
- MRUS Strong Buy
- Analyst Count
- VRNS 17
- MRUS 13
- Target Price
- VRNS $62.65
- MRUS $90.92
- AVG Volume (30 Days)
- VRNS 1.3M
- MRUS 542.5K
- Earning Date
- VRNS 10-28-2025
- MRUS 10-30-2025
- Dividend Yield
- VRNS N/A
- MRUS N/A
- EPS Growth
- VRNS N/A
- MRUS N/A
- EPS
- VRNS N/A
- MRUS N/A
- Revenue
- VRNS $595,168,000.00
- MRUS $56,228,000.00
- Revenue This Year
- VRNS $15.77
- MRUS $57.42
- Revenue Next Year
- VRNS $17.48
- MRUS $0.23
- P/E Ratio
- VRNS N/A
- MRUS N/A
- Revenue Growth
- VRNS 14.29
- MRUS 59.77
- 52 Week Low
- VRNS $36.53
- MRUS $33.19
- 52 Week High
- VRNS $60.58
- MRUS $70.41
- Technical
- Relative Strength Index (RSI)
- VRNS 49.00
- MRUS 59.95
- Support Level
- VRNS $55.80
- MRUS $65.74
- Resistance Level
- VRNS $57.87
- MRUS $70.65
- Average True Range (ATR)
- VRNS 1.55
- MRUS 2.41
- MACD
- VRNS -0.32
- MRUS 0.06
- Stochastic Oscillator
- VRNS 37.68
- MRUS 79.39
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.